Aurora A kinase and gynecological tumors

doi:10.3760/cma.j.issn.1673-422X.2014.02.012

Abstract

Abstract: Aurora A is a key serine/threonine kinase regulating cell cycle, which is involved in various procedures of mitosis, strictly depending on cell cycle. The single nucleotide polymorphisms (SNP) of AURKA gene and the aberrant expression of its encoding product Aurora A kinase are often closely related with the tumorigenesis, progression and prognosis of gynecological tumors, such as ovarian cancer, endometrial cancer, cervical cancer and sarcoma of uterus. Aurora A has become an ideal target for the targeted therapy of gynecological tumors.

Key words: Ovarian neoplasms, Endometrial neoplasms, Cervical , neoplasms, Aurora A kinase

Wang Kaiyue, Zhou Huaijun. Aurora A kinase and gynecological tumors[J]. Journal of International Oncology, 2014, 41(2): 117-120.

References

［1］ Vader G, Lens SM. The Aurora kinase family in cell division and cancer［J］. Biochim Biophys Acta, 2008, 1786(1): 60-72. ［2］ Karthigeyan D, Prasad SB, Shandilya J, et al. Biology of Aurora A kinase: implications in cancer manifestation and therapy［J］. Med Res Rev, 2011, 31(5): 757-793. ［3］ Nikonova AS, Astsaturov I, Serebriiskii IG, et al. Aurora A kinase (AURKA) in normal and pathological cell division［J］. Cell Mol Life Sci, 2013, 70(4): 661-687. ［4］ Zheng L, Song A, Ruan Y, et al. Genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 are associated with ovarian cancer susceptibility among Chinese Han women［J］. Cancer Epidemiol, 2013, 37(5): 639-646. ［5］ EwartToland A, Dai Q, Gao YT, et al. AuroraA/STK15 T+91A is a general low penetrance cancer susceptibility gene: a metaanalysis of multiple cancer types［J］. Carcinogenesis, 2005, 26(8): 1368-1373. ［6］ Shi H, Bevier M, Johansson R, et al. Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome［J］. Breast Cancer Res Treat, 2011, 130(3): 905-916. ［7］ Sun H, Bai J, Chen F, et al. Lack of an association between AURKA T91A polymorphisms and breast cancer: a metaanalysis involving 32 141 subjects［J］. Breast Cancer Res Treat, 2011, 125(1): 175-179. ［8］ Ramus SJ, Vierkant RA, Johnatty SE, et al. Consortium analysis of 7 candidate SNPs for ovarian cancer［J］. Int J Cancer, 2008, 123(2): 380-388. ［9］ Milam MR, Gu J, Yang H, et al. STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study［J］. Gynecol Onco, 2007, 107(1): 71-74. ［10］ Shan W, Akinfenwa PY, Savannah KB, et al. A smallmolecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma［J］. Clin Cancer Res, 2012, 18(12): 3352-3365. ［11］ Brewer Savannah KJ, Demicco EG, Lusby K, et al. Dual targeting of mTOR and auroraA kinase for the treatment of uterine Leiomyosarcoma［J］. Clin Cancer Res, 2012, 18(17): 4633-4645. ［12］ Zhang W, Wang J, Liu SJ, et al. Correlation between AuroraA expression and the prognosis of cervical carcinoma patients［J］. Acta Obstet Gynecol Scand, 2009, 88(5): 521-527. ［13］ Twu NF, Yuan CC, Yen MS, et al. Expression of Aurora kinase A and B in normal and malignant cervical tissue: high Aurora A kinase expression in squamous cervical cancer［J］. Eur J Obstet Gynecol Reprod Biol, 2009, 142(1): 57-63. ［14］ Lassus H, Staff S, Leminen A, et al. AuroraA overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma［J］. Gynecol Oncol, 2011, 120(1): 11-17. ［15］ Landen CN Jr, Lin YG, Immaneni A, et al. Overexpression of the centrosomal protein AuroraA kinase is associated with poor prognosis in epithelial ovarian cancer patients［J］. Clin Cancer Res, 2007, 13(14): 4098-4104. ［16］ Kulkarni AA, Loddo M, Leo E, et al. DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma［J. Clin Cancer Res, 2007, 13(20): 6153-6161. ［17］ Mendiola M, Barriuso J, MarioEnríquez A, et al. Aurora kinases as prognostic biomarkers in ovarian carcinoma［J］. Hum Pathol, 2009, 40(5): 631-638. ［18］ Lassmann S, Shen Y, Jütting U, et al. Predictive value of AuroraA/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy［J. Clin Cancer Res, 2007, 13(14): 4083-4091. ［19］ Yang F, Guo X, Yang G, et al. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma［J］. Mod Pathol, 2011, 24(6): 836845. ［20］ Matulonis UA, Sharma S, Ghamande S, et al. Phase Ⅱ study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinumresistant or refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma［J］. Gynecol Oncol, 2012, 127(1): 63-69. ［21］ Kurai M, Shiozawa T, Shih HC, et al. Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma［J］. Hum Pathol, 2005, 36(12): 1281-1288. ［22］ Llobet D, Pallares J, Yeramian A, et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints［J］. J Clin Pathol, 2009, 62(9): 777785. ［23］ MorenoBueno G, SánchezEstévez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas［J］. Cancer Res, 2003, 63(18): 5697-5702. ［24］ Shimomura T, Hasako S, Nakatsuru Y, et al. MK5108, a highly selective AuroraA kinase inhibitor, shows antitumor activity alone and in combination with docetaxel［J］. Mol Cancer Ther, 2010, 9(1): 157-166. ［25］ Chefetz I, Holmberg JC, Alvero AB, et al. Inhibition of AuroraA kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFκB pathway［J］. Cell Cycle, 2011, 10(13): 2206-2214.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.